Contact Us

Product Portfolio

Pulse Medical offers comprehensive imaging and computational physiology solutions for coronary and peripheral intervention workflows.

Comprehensive Coronary Intervention Solutions

Integrating CCTA, coronary angiography, IVUS, and computational physiology with multimodal data to cover full-process coronary intervention management — from screening and planning to navigation and post-procedural optimization.

Comprehensive Peripheral Intervention Solutions

Integrated solutions for preprocedural assessment, intraprocedural guidance, and postprocedural follow-up in peripheral interventions.

Featured Publication

Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial

The Lancet, 2021; 398, 2149-2159
Pulse's μFR-guided coronary PCI procedures can significantly reduce the one-year risk of post-procedural adverse events by 35%, alleviate patient burden while keeping medical expenditures under reasonable control, and hold substantial socio-health-economic value.

*μFR in China branded as QFR or μQFR

Featured Publication

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial

The Lancet, 2025; 405, 1491-1504
PCI strategy guided by Pulse's μFR — an angiography-based computed FFR derived from single-view angiography — including revascularization decision-making and procedural optimization — is non-inferior to IVUS-guided PCI in 12-month clinical outcomes and carries the added advantage of reducing stent implantation.

*μFR in China branded as QFR or μQFR

Featured Publication

Angiography-derived fractional flow reserve versus coronaryangiography to guide coronary artery bypass grafting in patientsundergoing surgical valve procedures with concomitant coronaryartery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial

The Lancet, 2026; 407, 1161-1170
Compared with the conventional coronary angiography-guided strategy, coronary artery bypass grafting (CABG, bypass surgery) guided by Pulse's μFR technology significantly improves postoperative clinical outcomes in patients with concomitant valvular disease and coronary artery disease.

*μFR in China branded as QFR or μQFR

Featured Publication

Complete Revascularization Guided by Functional Coronary Angiography in STEMI

N Engl J Med, 2026; DOI: 10.1056/NEJMoa2605373
The AIR-STEMI trial (n=1823) demonstrates that Pulse's μFR - guided complete revascularization in STEMI multivessel disease reduces major adverse events by 38% (8.9% vs 13.7%, P<0.001) and contrast-associated kidney injury with major bleeding, offering a safer strategy.

*μFR in China branded as QFR or μQFR

Featured Publication

2024 ESC Guidelines for the management of chronic coronary syndromes

European Heart Journal (2024) 00, 1-123
Pulse's μFR technology was formally incorporated and received a Class I (the highest-level) recommendation.

*μFR in China branded as QFR or μQFR

Featured Publication

Guidelines for percutaneous coronary intervention (2025)

Zhonghua Xin Xue Guan Bing Za Zhi. 2025 Jul 24;53(7):717-745.
Pulse's μFR technology, backed by its exceptional clinical value and robust evidence-based data, is explicitly recommended by current guidelines (Class I, Level A) for coronary physiological assessment and has become one of the key tools guiding PCI (percutaneous coronary intervention) decision-making.

*μFR in China branded as QFR or μQFR

Featured Publication

Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology

EuroIntervention, 2023;19:464-481; DOI: 10.4244/EIJ-D-23-00194
The EAPCI European expert consensus states that Pulse's μFR technology is the only angiography-based physiological index prospectively validated and demonstrated to improve clinical outcomes, applicable for pre-PCI planning, virtual stenting simulation, and post-PCI functional assessment to guide precision intervention.

*μFR in China branded as QFR or μQFR

Featured Publication

Practical Application of Coronary Physiologic Assessment: Asia-Pacific Expert Consensus Document: Part 1

JACC: Asia, 2023;3(5):689-706; DOI: 10.1016/j.jacasi.2023.07.003
The Asia-Pacific expert consensus describes image-based physiologic assessment including Pulse's μFR technology. Based on FAVOR III China and other studies, it recommends QFR-guided PCI to reduce stent implantation and improve outcomes, supporting virtual stenting planning and post-procedural verification.

*μFR in China branded as QFR or μQFR

Pulse Medical at ISICAM 2026 | Advancing 3D IVUS in Indonesia

2026-11-13

  • Insights into Precision PCI: Pulse IVUS Live Case and Launch Workshops in Vietnam

    2026-11-10

  • TCT 2026 —— Pulse Medical Highlights Multi-Dimensional Clinical Evidence at

    2026-11-09

  • CIAT 2026 | From Data to Decision: Dr. Mann Chandavimol Highlights μFR Technology in Complex PCI

    2026-11-06

  • Operators First, Imaging Empowers: A Milestone Live Case at CCT 2026

    2026-11-04

  • What if a routine angiogram may predict the future culprit vessel of a heart attack -- years before it happens?

    2026-11-03